Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam

References

• Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016 Dec;128:43–47.
   PubMed Web of Science ®Google Scholar
• Bayat A, Hjalgrim H, Moller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1: 22,000: a population-based study from 2004 to 2009. Epilepsia. 2015 Apr;56(4):e36–9.
   PubMed Web of Science ®Google Scholar
• Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015 Nov;136(5):e1310–5.
   PubMed Web of Science ®Google Scholar
• Xu X, Yang X, Wu Q, et al. Amplicon resequencing identified parental mosaicism for approximately 10% of “de novo” SCN1A mutations in children with Dravet Syndrome. Hum Mutat. 2015 Sep;36(9):861–872.
   PubMed Web of Science ®Google Scholar
• Mei D, Cetica V, Marini C, et al. Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies. Epilepsia. 2019 Dec;60(3):S2–7.
   PubMedGoogle Scholar
• Cross JH, Caraballo RH, Nabbout R, et al. Dravet syndrome: treatment options and management of prolonged seizures. Epilepsia. 2019 Dec;60(3):S39–48.
   PubMedGoogle Scholar
• Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet Syndrome: recommendations from a North American Consensus panel. Pediatr Neurol. 2017 Mar;68:18–34 e3.
   PubMed Web of Science ®Google Scholar
• Cardenal-Munoz E, Auvin S, Villanueva V, et al. Guidance on Dravet syndrome from infant to adult care: road map for treatment planning in Europe. Epilepsia Open. 2022 Mar;7(1):11–26.
   PubMedGoogle Scholar
• Ec W, Hood V, Knupp KG, et al. International consensus on diagnosis and management of Dravet syndrome. Epilepsia. 2022 Jul;63(7):1761–1777. 10.1111/epi.17274.
   PubMedGoogle Scholar
• Wirrell E, Tinuper P, Perucca E, et al. Introduction to the epilepsy syndrome papers. Epilepsia. 2022 Jun;63(6):1330–1332.
   PubMed Web of Science ®Google Scholar
• Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015 Jan;109:81–89.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009 Nov;50(11):2362–8. 10.1111/j.1528-1167.2009.02179.x.
   PubMed Web of Science ®Google Scholar
• Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2019 Dec 21;394(10216):2243–2254.
   PubMed Web of Science ®Google Scholar
• Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet Syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020 Mar 1;77(3):300–308.
   PubMed Web of Science ®Google Scholar
• Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla((r))) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study. Epilepsia. 2020 Nov;61(11):2396–2404.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for drug-resistant seizures in the Dravet Syndrome. N Engl J Med. 2017 May 25;376(21):2011–2020.
   PubMed Web of Science ®Google Scholar
• Miller I, Scheffer IE, Gunning B, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020 May 1;77(5):613–621.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial. Epilepsia. 2019 Feb;60(2):294–302.
   PubMed Web of Science ®Google Scholar
• Coppola G, Capovilla G, Montagnini A, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002 Mar;49(1):45–48.
   PubMed Web of Science ®Google Scholar
• Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000 Dec;9(8):590–594.
   PubMed Web of Science ®Google Scholar
• Kroll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006 Dec;37(6):325–329.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Takahashi Y, Mine J, et al. Effectiveness of topiramate in eleven patients with Dravet syndrome. No To Hattatsu. 2010 Jul;42(4):273–276.
   PubMedGoogle Scholar
• Wang YQ, Fang ZX, Zhang YW, et al. Efficacy of the ketogenic diet in patients with Dravet syndrome: a meta-analysis. Seizure. 2020 Oct;81:36–42.
   PubMed Web of Science ®Google Scholar
• Nickels KC, Wirrell EC. Stiripentol in the management of epilepsy. CNS Drugs. 2017 May;31(5):405–416.
   PubMed Web of Science ®Google Scholar
• Chiron C. Stiripentol expert opin investig drugs. Jul. 2005;14(7):905–911. DOI:10.1517/13543784.14.7.905
   Google Scholar
• Fisher JL. The effects of stiripentol on GABA(A) receptors. Epilepsia. 2011 Apr;52(2(0 2)):76–78. 10.1111/j.1528-1167.2011.03008.x.
   PubMedGoogle Scholar
• Riban V, Heulard I, Reversat L, et al. Stiripentol inhibits spike-and-wave discharges in animal models of absence seizures: a new mechanism of action involving T-type calcium channels. Epilepsia. 2022 May;63(5):1200–1210.
   PubMedGoogle Scholar
• Auvin S, Lecointe C, Dupuis N, et al. Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain. Epilepsia. 2013 Dec;54(12):2082–2090. 10.1111/epi.12401.
   PubMed Web of Science ®Google Scholar
• Verleye M, Buttigieg D, Steinschneider R. Neuroprotective activity of stiripentol with a possible involvement of voltage-dependent calcium and sodium channels. J Neurosci Res. 2016 Feb;94(2):179–189. 10.1002/jnr.23688.
   PubMed Web of Science ®Google Scholar
• Shin MC, Lee TK, Lee JC, et al. Therapeutic effects of stiripentol against ischemia-reperfusion injury in gerbils focusing on cognitive deficit, neuronal death, astrocyte damage and blood brain barrier leakage in the hippocampus. Korean J Physiol Pharmacol. 2022 Jan 1;26(1):47–57. DOI:10.4196/kjpp.2022.26.1.47
   PubMedGoogle Scholar
• Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997 Nov;62(5):490–504.
   PubMed Web of Science ®Google Scholar
• Giraud C, Treluyer JM, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006 Apr;34(4):608–611.
   PubMed Web of Science ®Google Scholar
• Klein P, Tolbert D, Gidal BE. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy Behav. 2019 Oct;99:106459. 10.1016/j.yebeh.2019.106459.
   PubMed Web of Science ®Google Scholar
• Boyd B, Smith S, Gammaitoni A, et al. A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther. 2019 Jan;57(1):11–19.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Gunning B, Arenas Cabrera CM, et al. A phase II randomized trial to explore the potential for pharmacokinetic drug-drug interactions with stiripentol or valproate when combined with Cannabidiol in patients with epilepsy. CNS Drugs. 2020 Jun;34(6):661–672.
   PubMed Web of Science ®Google Scholar
• Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986 Nov;14(6):654–662.
   PubMed Web of Science ®Google Scholar
• May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012 Aug;34(4):390–397.
   PubMed Web of Science ®Google Scholar
• Farwell JR, Anderson GD, Kerr BM, et al. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993 Mar;34(2):305–311.
   PubMed Web of Science ®Google Scholar
• Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000 Nov 11;356(9242):1638–1642. 3-21. years. 10.1016/S0140-6736(00)03157-3.
   PubMedGoogle Scholar
• Center for Drug Evaluation and Research. Application number: 206709orig1s000 207223orig1s000 Clin. Rev. 2018 [cited 2022 Nov 2, 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206709Orig1s000%2c207223Orig1s000MedR.pdf. .
   Google Scholar
• Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999 Nov;40(11):1618–1626. 10.1111/j.1528-1157.1999.tb02048.x.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y. Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence. Epilepsy Res. 2014 May;108(4):725–731.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Ohtsuka Y. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res. 2015 Jul;113:90–97. 10.1016/j.eplepsyres.2015.03.012.
   PubMed Web of Science ®Google Scholar
• Myers KA, Lightfoot P, Patil SG, et al. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018 Jun;60(6):574–578.
   PubMed Web of Science ®Google Scholar
• Wirrell EC, Laux L, Franz DN, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013 Sep;54(9):1595–1604. 10.1111/epi.12303.
   PubMed Web of Science ®Google Scholar
• Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet’s syndrome). Arch Pediatr. 2002 Nov;9(11):1120–1127.
   PubMed Web of Science ®Google Scholar
• De Liso P, Chemaly N, Laschet J, et al. Patients with dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res. 2016 Sep;125:42–46.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A, Schubert-Bast S, Reese JP, et al. Evaluation of health-care utilization in patients with Dravet syndrome and on adjunctive treatment with stiripentol and clobazam. Epilepsy Behav. 2014 May;34:86–91.
   PubMed Web of Science ®Google Scholar
• Kim H Abstract 2.089 efficacy and tolerability of stiripentol for the treatment of Dravet syndrome. American Epilepsy Society 2016: American Epilepsy Society 2016. Available from: https://www.aesnet.org/abstractslisting/efficacy-and-tolerability-of-stiripentol-for-the-treatment-of-dravet-syndrome
   Google Scholar
• Balestrini S, Sisodiya SM. Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurol Scand. 2017 Jan;135(1):73–79.
   PubMed Web of Science ®Google Scholar
• Chiron C, Helias M, Kaminska A, et al. Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood? Epilepsia. 2018 Sep;59(9):1705–1717. 10.1111/epi.14536.
   PubMed Web of Science ®Google Scholar
• Cho MJ, Kwon SS, Ko A, et al. Efficacy of stiripentol in Dravet syndrome with or without SCN1A mutations. J Clin Neurol. 2018 Jan;14(1):22–28.
   PubMedGoogle Scholar
• Yıldız EP, Ozkan MU, Uzunhan TA, et al. Efficacy of stiripentol and the clinical outcome in Dravet syndrome. J Child Neurol. 2019 Jan;34(1):33–37.
   PubMedGoogle Scholar
• Yamada M, Suzuki K, Matsui D, et al. Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: interim report of a post-marketing surveillance study in Japan. Epilepsy Res. 2021 Feb;170:106535.
   PubMedGoogle Scholar
• Chiron C, Nabbout R Abstract V.074 real world 30y-experience of using stiripentol before 2 years of age in patients with Dravet syndrome in France. American Epilepsy Society 2021: American Epilepsy Society; 2021. Available from: https://cms.aesnet.org/abstractslisting/real-world-30y-experience-of-using-stiripentol-before-2-years-of-age-in-patients-with-dravet-syndrome-in-france
   Google Scholar
• Balestrini S, Doccini V, Boncristiano A, et al. Efficacy and safety of long-term treatment with stiripentol in children and adults with drug-resistant epilepsies: a retrospective cohort study of 196 patients. Drugs Real World Outcomes. 2022 Sep;9(3):451–461.
   PubMedGoogle Scholar
• Nabbout R, Chironc C Abstract 3.426 starting stiripentol before 2 years of age, a clear benefit for patients with Dravet syndrome. American Epilepsy Society 2022 2022. Available from: https://cms.aesnet.org/abstractslisting/starting-stiripentol-before-2-years-of-age–a-clear-benefit-for-patients-with-dravet-syndrome.
   Google Scholar
• Chiron C. Stiripentol and vigabatrin current roles in the treatment of epilepsy. Expert Opin Pharmacother. 2016 Jun;17(8):1091–1101.
   PubMed Web of Science ®Google Scholar
• Levy RH, Rettenmeier AW, Anderson GD, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther. 1990 Sep;48(3):225–235.
   PubMed Web of Science ®Google Scholar